WANG Ning, Michael (王寧) Assistant Professor School of Chinese Medicine The University of Hong Kong CONTACT INFORMATION Address: School of Chinese Medicine, 10 Sassoon Road, Pokfulam, Hong Kong Tel: (852) 3917 6441 Fax: (852) 2872 5476 Email: [email protected] ACADEMIC QUALIFICATIONS 09/2002 - 08/2006 Bachelor of Science in Biotechnology (Sun Yat-sen University, China) 09/2006 - 08/2008 Master of Science in Pharmaceutical Science (Sun Yat-sen University, China) 09/2008 - 06/2012 Doctor of Philosophy in Pharmacology (The University of Hong Kong, Hong Kong) WORK EXPERIENCE 08/2018 – Present Assistant Professor, School of Chinese Medicine, The University of Hong Kong 08/2015 – 07/2018 Research Assistant Professor, School of Chinese Medicine, The University of Hong Kong 05/2014 – 07/2014 Visiting Research Fellow, School of Medicine, King’s College London, UK 08/2012 – 07/2015 Post-Doctoral Fellow, School of Chinese Medicine, The University of Hong Kong AREA OF EXPERTISE Pharmacology of plant-based natural products ACADEMIC AND PROFESSIONAL MEMBERSHIP - European Association for Cancer Research (2012-) - World Association of Chinese Medicine for Immunology (2014-) - Hong Kong Association of Herbal Pharmacology (2017-) - British Pharmacological Society (2019-) - Fellowship of the Academy of Translational Medicine Professionals (2019-) CURRENT FEATURES OF WORK Teaching subjects: - Pharmacology of Chinese herbal medicine for Bachelor of Chinese Medicine and Bachelor of Pharmacy students - Field Trip & Chinese Medicine Dispensary Practicum - Chinese Materia Medica - Research Progress of Pharmacology and Toxicology of Chinese herbal Medicines Research fields: - Discovery of novel natural autophagy regulatory molecules from medicinal plants - Discovery of natural anti-cancer drug lead from medicinal plants - Discovery of natural compounds from medicinal plants for the treatment of metabolic disorders PUBLICATIONS (in chronological order, Citation record from Google Scholar) A. Peer-reviewed Journal Articles (*corresponding author) First/co-first or corresponding authorship 1. Lu Y, Chan YT, Tan HY, Li S, Wang N*, Feng Y*. Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy. Mol Cancer. Accepted for publication. (IF: 10.679). 2. Tan HY, Wang N (co-first author), Chan YT, Zhang C, Guo W, Chen F, Zhong Z, Li S, Feng Y*. ID1 overexpression increases gefitinib sensitivity in non-small cell lung cancer by activating RIP3/MLKL-dependent necroptosis. Cancer Lett. 2020; 475:109-118. (IF:6.508) 3. Wang N, Tan HY, Li S, Wang D, Xu Y, Zhang C, Xia W, Che CM, Feng Y*. Remission of Obesity-Induced Insulin Resistance via Modulating SBP2 Expression in Adipose Tissue Macrophages. Sci Adv, 2019, 5, eaav0198. (IF:12.804) 4. Wang N, Zhang C, Xu Y, Li S, Tan HY, Xia W, Feng Y*. OMICs approaches-assisted identification of macrophages-derived MIP-1γ as the therapeutic target of botanical products TNTL in diabetic retinopathy. Cell Commun Signal. 2019; 17(1):81. (IF:5.111) 5. Qu Y, Dou B, Tan H, Feng Y*, Wang N*, Wang D*. Tumor microenvironment-driven non-cell-autonomous resistance to antineoplastic treatment. Mol Cancer. 2019;18(1):69. (IF:10.697) 6. Jiang X, Tan HY, Teng S, Chan YT, Wang D*, Wang N*. The Role of AMP-Activated Protein Kinase as a Potential Target of Treatment of Hepatocellular Carcinoma. Cancers (Basel). 2019;11(5). pii: E647. (IF:6.162) 7. Wang N, Tan HY, Feng YG, Zhang C, Chen F, Feng Y*. microRNA-23a in Human Cancer: Its Roles, Mechanisms and Therapeutic Relevance. Cancers (Basel). 2018;11(1). pii: E7. (IF:6.162) 8. Wang N, Tan HY, Li S, Feng Y*. Atg9b Deficiency Suppresses Autophagy and Potentiates Endoplasmic Reticulum Stress-Associated Hepatocyte Apoptosis in Hepatocarcinogenesis. Theranostics, 2017; 7:2325-38. (IF:8.063) 9. Wang N, Tan HY, Li S, Xu Y, Guo W, Feng Y*. Supplementation of Micronutrient Selenium in Metabolic Diseases: Its Role as an Antioxidant. Oxid Med Cell Longev. 2017;2017:7478523. (IF:4.868) 10. Lan J, Wang N (co-first author), Huang L, Liu Y, Ma X, Lou H, Chen C, Feng Y*, Pan W*. Design and synthesis of novel tetrandrine derivatives as potential anti-tumor agents against human hepatocellular carcinoma. Eur J Med Chem. 2017;127:554-66. (IF:4.833) 11. Wang N, Tan HY, Chan YT, Guo W, Li S, Feng Y*. Identification of WT1 as determinant of heptatocellular carcinoma and its inhibition by Chinese herbal medicine Salvia chinensis Benth and its active ingredient protocatechualdehyde. Oncotarget. 2017;8(62):105848-59. 12. Wang N, Wang X, Tan HY, Li S, Tsang CM, Tsao SW, Feng Y*. Berberine Suppresses Cyclin D1 Expression through Proteasomal Degradation in Human Hepatoma Cells. Int J Mol Sci. 2016;17. pii: E1899. (IF:4.183) 13. Wang N, Xu Q, Tan HY, Hong M, Li S, Yuen MF, Feng Y. Berberine Inhibition of Fibrogenesis in a Rat Model of Liver Fibrosis and in Hepatic Stellate Cells. Evid Based Complement Alternat Med. 2016;2016:8762345. (IF:1.984) 14. Tan HY, Wang N (co-first author), Man K, Tsao SW, Che CM, Feng Y*. Autophagy-induced RelB/p52 activation mediates tumour-associated macrophage repolarisation and suppression of hepatocellular carcinoma by natural compound baicalin. Cell Death Dis. 2015;6:e1942. (IF:5.959) 15. Wang N, Tan HY, Li L, Yuen MF, Feng Y*. Berberine and Coptidis Rhizoma as potential anticancer agents: Recent updates and future perspectives. J Ethnopharmacol. 2015;176:35-48. (IF:3.414) 16. Wang N, Feng Y*, Tan HY, Cheung F, Hong M, Lao L, Nagamatsu T. Inhibition of eukaryotic elongation factor-2 confers to tumor suppression by a herbal formulation Huanglian-Jiedu decoction in human hepatocellular carcinoma. J Ethnopharmacol. 2015;164:309-18. (IF:3.414) 17. Wang N, Feng Y, Cheung F, Wang X, Zhang Z, Feng Y. A Chinese medicine formula Gegen Qinlian decoction suppresses expansion of human renal carcinoma with inhibition of matrix metalloproteinase-2. Integr Cancer Ther. 2015;14:75-85. (IF:2.634) 18. Wang N, Feng Y. Elaborating the role of natural products-induced autophagy in cancer treatment: achievements and artifacts in the state of the art. Biomed Res Int. 2015;2015:934207. (IF:2.197) 19. Wang N, Zhu M, Wang X, Tan HY, Tsao SW, Feng Y*. Berberine-induced tumor suppressor p53 up-regulation gets involved in the regulatory network of MIR-23a in hepatocellular carcinoma. Biochim Biophys Acta. 2014;1839:849-57. (IF:4.599) 20. Xu B, Wang N (co-first author), Pan W, Qiu J, Cao P, Zhu M, Feng Y*, Liang G*. Synthesis and anti-tumor activity evaluation of Matijin-Su derivatives. Bioorg Chem. 2014;56:34-40. (IF:3.926) 21. Wang N, Zhu M, Tsao SW, Man K, Zhang Z, Feng Y*. MiR-23a-mediated inhibition of topoisomerase 1 expression potentiates cell response to etoposide in human hepatocellular carcinoma. Mol Cancer. 2013;12:119. (IF:10.679) 22. Wang N, Feng Y*, Zhu M, Siu FM, Ng KM, Che CM. A novel mechanism of XIAP degradation induced by timosaponin AIII in hepatocellular carcinoma. Biochim Biophys Acta. 2013;1833:2890-9. (IF:4.739) 23. Wang N, Zhu M, Tsao SW, Man K, Zhang Z, Feng Y. Up-regulation of TIMP-1 by genipin inhibits MMP-2 activities and suppresses the metastatic potential of human hepatocellular carcinoma. PLoS One. 2012;7:e46318. (IF:2.771) 24. Wang N, Feng Y, Cheung F, Chow OY, Wang X, Su W, Tong Y. A comparative study on the hepatoprotective action of bear bile and Coptidis Rhizoma aqueous extract on experimental liver fibrosis in rats. BMC Complement Altern Med. 2012;12:239. (IF:2.479) 25. Wang N, Pan W, Zhu M, Zhang M, Hao X, Liang G*, Feng Y*. Fangchinoline induces autophagic cell death via p53/sestrin2/AMPK signalling in human hepatocellular carcinoma cells. Br J Pharmacol. 2011;164:731-42. (IF:6.583) 26. Wang N, Feng Y, Xie TN, Su W, Zhu M, Chow O, Zhang Y, Ng KM, Leung CH, Tong Y. Chemical and biological analysis of active free and conjugated bile acids in animal bile using HPLC-ELSD and MTT methods. Exp Ther Med. 2011; 2:125-30. (IF:1.448) 27. Wang N, Feng Y*, Zhu M, Tsang CM, Man K, Tong Y, Tsao SW. Berberine induces autophagic cell death and mitochondrial apoptosis in liver cancer cells: the cellular mechanism. J Cell Biochem. 2010;111:1426-36. (IF:3.448) 28. Wang N, Feng Y, Lau EP, Tsang C, Ching Y, Man K, Tong Y, Nagamatsu T, Su W, Tsao S. F-actin reorganization and inactivation of rho signaling pathway involved in the inhibitory effect of Coptidis Rhizoma on hepatoma cell migration. Integr Cancer Ther. 2010; 9:354-64. (IF:2.634) 29. Wang N, Li P, Wang Y, Peng W, Wu Z, Tan S, Liang S, Shen X, Su W*. Hepatoprotective effect of Hypericum japonicum extract and its fractions. J Ethnopharmacol. 2008;116:1-6. (IF:3.414) Co-authorship 30. Huang J, Chen F, Zhong Z, Tan HY, Wang N, Liu Y, Fang X, Yang T, Feng Y. Interpreting the Pharmacological Mechanisms of Huachansu Capsules on Hepatocellular Carcinoma Through Combining Network Pharmacology and Experimental Evaluation. Front Pharmacol. 2020 Apr 3;11:414. (IF:3.845) 31. Chan YT, Cheung F, Zhang C, Fu B, Tan HY, Norimoto H, Wang N, Feng Y. Ancient Chinese Medicine Herbal Formula Huanglian Jiedu Decoction as a Neoadjuvant Treatment of Chemotherapy by Improving Diarrhea and Tumor Response. Front Pharmacol. 2020 Mar 10;11:252. (IF:3.845) 32. Zhang D, Li S, Wang N, Tan HY, Zhang Z, Feng Y. The Cross-Talk Between Gut Microbiota and Lungs in Common Lung Diseases. Front Microbiol. 2020 Feb 25;11:301. (IF:4.259) 33. Xu Y, Wang N, Tan HY, Li S, Zhang C, Feng Y.